An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zepzelca

Chemical Namelurbinectedin
Dosage FormInjection (intravenous; 4 mg)
Drug ClassAlkylating agents
SystemRespiratory
CompanyPharma Mar
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zepzelca (lurbinectedin) Prescribing Information.2020Jazz Pharmaceuticals, Inc. Palo Alto, CA
Document TitleYearSource
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin versus cyclophosphamide, doxorubicin and vincristine (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line (ATLANTIS).2020PharmaMar
Document TitleYearSource
SEOM clinical guidelines for the treatment of small‑cell lung cancer (SCLC) (2019).2020Clinical and Translational Oncology